Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5- methyl-1, 3, 4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site

Protein Science

Volumn 14, Issue 4, 2005, Pages 873-888

  Chrysina, Evangelia D ^a   Kosmopoulou, Magda N ^a   Tiraidis, Constantinos ^a   Kardakaris, Rozina ^a   Bischler, Nicolas ^a   Leonidas, Demetres D ^a   Hadady, Zsuzsa ^b   Somsak, Laszlo ^b   Docsa, Tibor ^c   Gergely, Pal ^c   Oikonomakos, Nikos G ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

D glucopyranosyl analogs; Glycogen phosphorylase; Inhibition; Type 2 diabetes; X ray crystallography

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; GLUCOSE DERIVATIVE; GLYCOGEN PHOSPHORYLASE B; HYDROGEN; INDOLE;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG INTERACTION; DRUG POTENCY; HYDROGEN BOND; HYPERGLYCEMIA; KINETICS; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; X RAY CRYSTALLOGRAPHY;

BENZIMIDAZOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; GLUCOSIDES; KINETICS; MODELS, MOLECULAR; OXADIAZOLES; PHOSPHORYLASE B; THIAZOLES;

EID: 20144373860     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.041216105     Document Type: Article

References (32)

1. Aiston, S., Hampson, L., Gómez-Foix, A.M., Guinovart, J.J., and Agius, L. 2001. Hepatic glycogen synthesis is highly sensitive to phosphorylase activity. J. Biol. Chem. 276: 23858-23866.
2. Aiston, S., Coghlan, M.P., and Agius, L. 2003. Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. Eur. J. Biochem. 270: 2773-2781.
3. Bichard, C.J.F., Mitchell, E.P., Wormald, M.R., Watson, K.A., Johnson, L.N., Zographos, S.E., Koutra, D.D., Oikonomakos, N.G., and Fleet, G.W.J. 1995. Potent inhibition of glycogen phosphorylase by a spirohydantoin of glucopyranose: First pyranose analogues of hydantocidin. Tetrahedron Lett. 36: 2145-2148.
4. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography and NMR system; A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921.
5. Collaborative Computing Project Number 4. 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
6. Chrysina, E.D., Oikonomakos, N.G., Zographos, S.E., Kosmopoulou, M.N., Bischler, N., Leonidas, D.D., Kovács, L., Docsa, T., Gergely, P., and Somsák, L. 2003. Crystallographic studies on α- and β-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase. Biocatal. Biotransfor. 21: 233-242.
7. Chrysina, E.D., Kosmopoulou, M.N., Kardakaris, R., Bischler, N., Leonidas, D.D., Kannan, T., Loganathan, D., and Oikonomakos, N.G. 2004. Binding of β-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: Kinetic and crystallographic studies. Bioorg. Med. Chem. 13: 765-772.
8. Esnouf, R.M. 1997. An extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15: 132-134.
9. Gregoriou, M., Noble, M.E.M., Watson, K.A., Carman, E.F., Krulle, T.M., Fuente, C., Fleet, G.W.J., Oikonomakos, N.G., and Johnson, L.N. 1998. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K: The role of the water structure and its contribution to binding. Protein Sci. 7: 915-927.
10. Györgydeák, Z., Hadady, Z., Felföldi, N., Krakomperger, A., Nagy, V., Tóth, M., Brunyánszki, A., Docsa, T., Gergely, P., and Somsák, L. 2004. Synthesis of N-(β-D-glucopyranosyl)-and N-(2-acetamido-2-deoxy-β-D-glucopyranosyl)amides as inhibitors of glycogen phosphorylase. Bioorg. Med. Chem. 12: 4861-4870.
11. Hadady, Zs., Tóth, M., and Somsák, L. 2004. C-(β-D-Glucopyranosyl) heterocycles as potential glycogen phosphorylase inhibitors. Arkivoc vii: 140-149.
12. Johnson, L.N. and Lewis, R.J. 2001. Structural basis for control by phosphorylation. Chem. Rev. 101: 2209-2242.
13. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
14. Kraulis, P. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946-950.
15. Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. 1993. PROCHECK-A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283-291.
16. Latsis, T., Andersen, B., and Agius, L. 2002. Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes. Biochem. J. 368: 309-316.
17. Luzatti, V. 1952. Traitement statistique des erreurs dans la determination des structure crystallines. Acta Crystallogr. 5: 802-810.
18. Martin, J.L., Veluraja, K., Johnson, L.N., Fleet, G.W.J., Ramsden, N.G., Bruce, I., Oikonomakos, N.G., Papageorgiou, A.C., Leonidas, D.D., and Tsitoura, H.S. 1991. Glucose analogue inhibitors of glycogen phosphorylase: The design of potential drugs for diabetes. Biochemistry 30: 10101-10116.
19. Merritt, E.A. and Bacon, D.J. 1997. Raster3D: Photorealistic molecular graphics. Methods Enzymol. 277: 505-524.
20. Oikonomakos, N.G. 2002. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr. Protein Pept. Sci. 3: 561-586.
21. Oikonomakos, N.G., Melpidou, A.E., and Johnson, L.N. 1985. Crystallisation of pig skeletal phosphorylase b. Biochim. Biophys. Acta 832: 248-256.
22. Oikonomakos, N.G., Kontou, M., Zographos, S.E., Watson, K.A., Johnson, L.N., Bichard, C.J.F., Fleet, G.W.J., and Acharya, K.R. 1995. N-acetyl-β-D-glucopyranosylamine: A potent T state inhibitor of glycogen phosphorylase. A comparison with α-D-glucose. Protein Sci. 4: 2469-2477.
23. Oikonomakos, N.G., Skamnaki, V.T., Tsitsanou, K.E., Gavalas, N.G., and Johnson, L.N. 2000. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 8: 575-584.
24. Oikonomakos, N.G., Skamnaki, V.T., Ösz, E., Szilágyi, L., Somsák, L., Docsa, T., Tóth, B., and Gergely, P. 2002a. Kinetic and crystallographic studies of glucopyranosylidene spirothiohydantoin binding to glycogen phosphorylase b. Bioorg. Med. Chem. 10: 261-268.
25. Oikonomakos, N.G., Kosmopoulou, M., Zographos, S.E., Leonidas, D.D., Chrysina, E.D., Somsák, L., Nagy, V., Praly, J.-P., Docsa, T., Tóth, B., et al. 2002b. The binding of N'-acetyl- and Benzoyl-N'-β-D-glucopyranosyl ureas to glycogen phosphorylase b: Kinetic and crystallographic studies. Eur. J. Biochem. 269: 1-13.
26. Otwinowski, Z. and Minor, W. 1997. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
27. Rath, V.L., Ammirati, M., Danley, D.E., Ekstrom, J.L., Gibbs, E.M., Hynes, T.R., Mathiowetz, A.M., McPherson, R.K., Olson, T.V., Treadway, J.L., et al. 2000a. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7: 677-682.
28. Rath, V.L., Ammirati, M., LeMotte, P.K., Fennell, K.F., Mansour, M.N., Danley, D.E., Hynes, T.R., Schulte, G.K., Wasilko, D.J., and Pandit, J. 2000b. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol Cell. 1: 139-148.
29. Somsák, L., Kovács, L., Tóth, M., Ösz, E., Szilágyi, L., Györgydeák, Z., Dinya, Z., Docsa, T., Tóth, B., and Gergely, P. 2001. Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of D-gluco- and D-xylopyranosylidene-spiro-(thio)hydantoins and N-(D-glucopyranosyl) amides. J. Med. Chem. 44: 2843-2848.
30. Somsák, L., Nagy, V., Hadady, Z., Docsa, T., and Gergely, P. 2003. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: Recent developments. Curr. Pharm. Des. 9: 1177-1189.
31. Watson, K.A., Mitchell, E.P., Johnson, L.N., Son, J.C., Bichard, C.J.F., Orchard, M.G., Fleet, G.W.J., Oikonomakos, N.G., Leonidas, D.D., Kontou, M., et al. 1994. Design of inhibitors of glycogen phosphorylase: A study of α- and β-C-glucosides and 1-thio-β-D-glucose compounds. Biochemistry 33: 5745-5758.
32. Watson, K.A., Mitchell, E.P., Johnson, L.N., Cruciani, G., Son, J.C., Bichard, C.J.F., Fleet, G.W.J., Oikonomakos, N.G., Kontou, M., and Zographos, S.E. 1995. Glucose analogue inhibitors of glycogen phosphorylase: From crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. Acta Cryslallogr. D Biol. Crystallogr. 51: 458-472.